ClinicalTrials.gg
Active, not recruitingNCT05186974EVOKE-02Updated Sep 11, 2026

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Sacituzumab Govitecan-hziy (SG) and Pembrolizumab in Non-small Cell Lung Cancer, sponsored by Gilead Sciences. Active, not recruiting at 101 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
193
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing sacituzumab govitecan in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 8 under way, 3 of them phase 3. sacituzumab govitecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 10
193 · median 193
Started
2022
the only one that year
Phase 2
5 of 10
3 open now
Registered
4th of 10
by date
Lead sponsor
4 of 10
Gilead Sciences

Among the 10 studies testing sacituzumab govitecan in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 10 studies testing sacituzumab govitecan in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About sacituzumab govitecan

sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing sacituzumab govitecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals with documented evidence of Stage IV non-small cell lung Cancer (NSCLC) disease at the time of enrollment
  • by computed tomography (CT) or magnetic resonance imaging (MRI) as per Version 1.1 criteria by investigator
  • No prior systemic treatment for NSCLC
  • (ECOG) performance status score of 0 or 1
  • Adequate hematologic counts
  • Adequate hepatic function

Key Exclusion Criteria:

  • Mixed SCLC and NSCLC histology
  • Active second
  • NSCLC that is eligible for definitive local therapy alone
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy
  • Has an active disease that has required systemic treatment in past 2 years
  • Has had an allogenic tissue/solid organ transplant.
  • Has severe (≥ Grade 3) to SG, pembrolizumab, carboplatin, or cisplatin, their metabolites, or formulation
  • Has received radiation therapy to the lung
  • Individuals may not have received systemic anticancer treatment within the previous 6 months
  • Is currently participating in or has participated in a study of an agent
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Known active central nervous system (CNS) metastases
  • History of cardiac disease
  • Active chronic inflammatory bowel disease
  • Active serious infection requiring antibiotics
  • Active or chronic infection
  • Positive antibody
  • Positive serum pregnancy test or women who are lactating

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    Sacituzumab Govitecan-hziy (SG) + Pembrolizumab (Cohort A)

    Participants assigned to Cohorts A according to tumor proportion score (TPS) status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy (SG) · Drug: Pembrolizumab

  • Experimental
    SG + Pembrolizumab (Cohort B)

    Participants assigned to Cohorts B according to TPS status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy (SG) · Drug: Pembrolizumab

  • Experimental
    SG + Pembrolizumab + Carboplatin Safety Run-in

    Participants will receive SG (de-escalating dose levels: 10.0 mg/kg, 7.5 mg/kg, or 5.0 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin area under the concentration versus time curve (AUC)5 on Day 1 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy (SG) · Drug: Pembrolizumab · Drug: Carboplatin

  • Experimental
    SG + Pembrolizumab + Cisplatin Safety Run-in (Optional)

    Participants will receive SG (either 10 mg/kg or 7.5 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/m\^2 on Day 1 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy (SG) · Drug: Pembrolizumab · Drug: Cisplatin

  • Experimental
    SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort C)

    Participants assigned to Cohort C according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m\^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy (SG) · Drug: Pembrolizumab · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort D)

    Participants assigned to Cohort D according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m\^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy (SG) · Drug: Pembrolizumab · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    SG + Pembrolizumab + Cisplatin (Cohort E)

    Participants assigned to Cohort E will receive SG RP2D, as determined following safety review of Cohorts C and D, on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/ m\^2 on Day 1 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy (SG) · Drug: Pembrolizumab · Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Time frame: Up to 22 Months

  2. Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts

    Time frame: First dose date up to 21 days

Secondary outcomes

  1. Progression-free Survival as Assessed by IRC per RECIST Version 1.1

    Time frame: Up to 24 Months

  2. Overall Survival

    Time frame: Up to 24 Months

  3. Duration of Response as Assessed by IRC per RECIST Version 1.1

    Time frame: Up to 24 Months

  4. Disease Control Rate as Assessed by IRC per RECIST Version 1.1

    Time frame: Up to 24 Months

  5. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose date up to 24 Months plus 30 days

  6. Percentage of Participants Experiencing Clinical Laboratory Abnormalities

    Time frame: First dose date up to 24 Months plus 30 days

07

Study locations

101 sites

Showing the first 100 of 101 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, Felip E, Cappuzzo F, Garon EB, Neal JW, Mekan S, Safavi F, Fernando N, Zavodovskaya M, Jurgensmeier JM, Chisamore M, Cho BC. First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. J Thorac Oncol. 2026 Mar;21(3):103509. doi: 10.1016/j.jtho.2025.10.016. Epub 2025 Oct 30. PubMed 41173143 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Mar 2027, 58 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 58 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2021
First posted
Jan 11, 2022
StartActual
May 30, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05186974
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
May 30, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion